ライフサイエンスコーパス: placebo

1 e monthly subcutaneous injections of evolocumab (420 mg) or placebo.

2 lure in a 1:1 ratio to receive either LY-CoV555 or matching placebo.

3 n to determine VO2 peak with lumbar intrathecal fentanyl or placebo.

4 ne, 55 patients received simple bupivacaine and 52 received placebo.

5 s, with 80 allocated to receive vitamin K and 79 to receive placebo.

6 s (4%) who received SNF472 and 5 patients (6%) who received placebo.

7 decrease in the plasma insulin concentration compared with placebo.

8 at 26 weeks (n = 523; 17% [300 mg] and 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and 1 trial of nicot

9 Patients (n=448) were randomized 1:1:1 to placebo, 25 mg of OM BID, or to pharmacokinetically guided do

10 rovement at month 18 vs baseline was higher in Cit-B12 than placebo (33% vs 15%, p = 0.04).

11 tients were randomized 1:1 to receive 25 mg clazakizumab or placebo (4-weekly subcutaneous injections) for 12 weeks (part

12 ained significantly improved with ramucirumab compared with placebo (4.1 months [95% CI 3.3-4.8] vs 2.8 months [2.6-2.9];

13 mokers into a double-blind clinical trial with four groups: placebo, 5 mg/d, 10 mg/d, and 20 mg/d of oral tropisetron.

14 ent randomization and received evolocumab (104 patients) or placebo (53 patients).

15 g groups, randomized 2:1 to receive two doses of TAK-003 or placebo 90 days apart.

16 diesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B in patients with nonsegm

17 zolizumab was achieved by means of an identical intravenous placebo, and blinding for vemurafenib was achieved by means o

18 66 +/- 0.11 mg/kg/min, P < 0.05) than in subjects receiving placebo, and it was associated with a significant increase in

19 ls with MDD and 22 healthy controls (HCs) at baseline, post-placebo, and post-ketamine.

20 mg] and 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and 1 trial of nicotine replacement therapy at 12 m

21 Compared with placebo, CBD was associated with an increased likelihood of w

22 en residing in the azithromycin communities, but not in the placebo communities.

23 This phase 3, double-blind, placebo-controlled study was done at 118 sites in 13 countrie

24 In this double-blind, placebo-controlled study, we investigated whether a single 10

25 This randomized, double-blind, placebo-controlled trial included patients with type 2 diabet

26 A factorial, randomized, double-blind, placebo-controlled trial was conducted in infertility clinics

27 In part 1 of this phase 2, randomized, placebo-controlled trial we sequentially enrolled 1.5-45 year

28 thesized that the u-opioid system-extensively implicated in placebo effects, a clinical phenomenon thought to rely on con

29 -72) in the pertuzumab group and 40.8 months (36-48) in the placebo group (hazard ratio 0.69, 95% CI 0.58-0.82); 8-year l

30 ignificantly shorter in the steroid group compared with the placebo group even though both groups included patients who w

31 CSF SOD1 concentration between the tofersen groups and the placebo group was 2 percentage points (95% confidence interva

32 sessed to be better in the melatonin group than that in the placebo group with a mean (SD) of 69.7 (21.2) and 60.7 (26.3)

33 60 (57%) of 104 patients in the placebo group, 63 (66%) of 96 in the ixekizumab Q4W group, an

34 5% CI 31-42) in the pertuzumab group and 23% (19-28) in the placebo group.

35 he IVIG group were responders, compared to zero of 6 in the placebo group.

36 tients were assigned to the SEP-363856 group and 125 to the placebo group.

37 One patient died by sudden death in the placebo group.

38 d the bandit task at baseline, and after methylphenidate or placebo in counter-balanced order.

39 brafenib plus trametinib reduced the risk of relapse versus placebo in patients with resected, BRAF(V600)-mutant, stage I

40 Galcanezumab was superior to placebo in the preventive treatment of migraine and was safe

41 d not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine.

42 intramuscular injections 28 days apart (20 ug, n = 201) or placebo (n = 199) and were followed up for 72 weeks.

43 mized to receive either 150 mg/d of resveratrol (n = 20) or placebo (n = 21) for 6 mo.

44 her a single dose of PCV20 followed 1 month later by saline placebo or a single dose of PCV13 followed 1 month later by 2

45 Eight RCTs of DAA therapy vs placebo or an outdated antiviral regimen, 48 other treatment

46 tinine levels tended to mildly increase (3% bezafibrate, 5% placebo, P = .14).

47 ter symptom onset led to lower 90-day mortality than use of placebo (relative risk, 0.19; 95% CI, 0.05 to 0.75), whereas

48 bo, and blinding for vemurafenib was achieved by means of a placebo tablet.

49 randomly assigned to receive luspatercept and 76 to receive placebo; the baseline characteristics of the patients were ba

50 receive 300 mg S44819 twice a day, and 193 (33%) to receive placebo twice a day.